Bristol Myers Squibb Raises Full-Year Revenue Forecast Following Strong Q2 Earnings
Bristol Myers Squibb reported second-quarter revenue of $12.97 billion, surpassing expectations and leading the company to raise its full-year revenue forecast from $46–$47.5 billion to $49–$50 billion. The performance was driven by strong sales in newer products like Eliquis, Reblozyl, and Camzyos, with Eliquis alone contributing $4.48 billion for the quarter—a 22% increase year-over-year.
Topics: earnings report guidance update pharmaceuticals revenue growth